Cerebrospinal fluid angiotensin II in patients with essential hypertension. 1988

M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Yamamoto, and K Ito
Division of Hypertension and Nephrology, National Cardiovascular Center, Osaka, Japan.

We measured components of the cerebrospinal fluid renin-angiotensin system from patients with essential hypertension under different dietary sodium intakes. The cerebrospinal fluid concentration of angiotensin II (Ang II) from the patients on a normal-sodium diet was 1.36 +/- 0.41 fmol/ml (n = 5). Neither the inactive nor the active form of renin was detected by the enzymatic activity or by the immunoreactivity, whereas angiotensinogen was detected (38.6 +/- 3.1 pmol/ml, n = 5). The Ang II level remained unchanged even after incubation of the cerebrospinal fluid at 37 degrees C for 3 h. Further, when authentic Ang II was added to the cerebrospinal fluid followed by incubation for 3 h at 37 degrees C, more than 90% of the added Ang II remained unchanged. Thus, the cerebrospinal fluid Ang II level may be reflected by the activity of the brain Ang II-forming system, as it was not affected by the cerebrospinal fluid constituents. The circulating renin-angiotensin system was stimulated by sodium depletion, and the cerebrospinal fluid concentration of Ang II also increased significantly. Sodium depletion may stimulate the brain Ang-II forming system, as it does the circulating renin-angiotensin system.

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000804 Angiotensin II An octapeptide that is a potent but labile vasoconstrictor. It is produced from angiotensin I after the removal of two amino acids at the C-terminal by ANGIOTENSIN CONVERTING ENZYME. The amino acid in position 5 varies in different species. To block VASOCONSTRICTION and HYPERTENSION effect of angiotensin II, patients are often treated with ACE INHIBITORS or with ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS. Angiotensin II, Ile(5)-,Angiotensin II, Val(5)-,5-L-Isoleucine Angiotensin II,ANG-(1-8)Octapeptide,Angiotensin II, Isoleucine(5)-,Angiotensin II, Valine(5)-,Angiotensin-(1-8) Octapeptide,Isoleucine(5)-Angiotensin,Isoleucyl(5)-Angiotensin II,Valyl(5)-Angiotensin II,5 L Isoleucine Angiotensin II,Angiotensin II, 5-L-Isoleucine
D012982 Sodium, Dietary Sodium or sodium compounds used in foods or as a food. The most frequently used compounds are sodium chloride or sodium glutamate. Dietary Sodium

Related Publications

M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Yamamoto, and K Ito
August 1976, Australian and New Zealand journal of medicine,
M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Yamamoto, and K Ito
August 1976, Australian and New Zealand journal of medicine,
M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Yamamoto, and K Ito
February 1977, British medical journal,
M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Yamamoto, and K Ito
September 1984, Life sciences,
M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Yamamoto, and K Ito
January 1982, Clinical and experimental hypertension. Part A, Theory and practice,
M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Yamamoto, and K Ito
February 1953, The Journal of laboratory and clinical medicine,
M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Yamamoto, and K Ito
January 1984, Clinical and experimental hypertension. Part A, Theory and practice,
M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Yamamoto, and K Ito
May 1980, Japanese heart journal,
M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Yamamoto, and K Ito
May 2008, Multiple sclerosis (Houndmills, Basingstoke, England),
M Kawamura, and Y Kawano, and K Yoshida, and M Imanishi, and S Akabane, and Y Matsushima, and M Kuramochi, and K Shimamoto, and K Yamamoto, and K Ito
October 1979, Nihon rinsho. Japanese journal of clinical medicine,
Copied contents to your clipboard!